Quest Diagnostics ($DGX) launched a digital tool for the assessment of cognitive dysfunction in dementia patients, which will address several challenges that come with paper-based cognitive assessment.
The tool, CogniSense, is intended to remedy limitations of traditional paper-based assessment, including the lack of objective and easily trackable data over time and the integration of electronic health records, Quest Diagnostics said in a statement.
It will provide a digitized version of the Memory Orientation Assessment Test, which is used to evaluate a patient’s cognitive health through a series of tests. These include tests using memory recall techniques, information comprehension tests and tablet-based clock drawing. Studies in more than 3,500 people have shown that MOST is superior to standard paper-based tests in sensitivity and specificity, Quest said.
"CogniSense addresses a gap in cognitive health assessment today--a lack of digital technology that seamlessly integrates results into a patient's electronic health records to track cognitive function and disease progression over time," said Dr. Edward Ginns, medical director of neurology atQuest Diagnostics, in the statement. "CogniSense's features enhance the efficiency and ease of cognitive assessment--especially in a primary care setting."
CogniSense is available as an iPad app and provides test scores that can be stored in Quest’s Care360 lab-ordering system as well as any electronic health records that connect to Quest. This allows doctors to monitor patients’ cognitive function over time. Quest is calling the combination of lab diagnostics and health IT “integrated diagnostics.”
"Integrated diagnostics will be increasingly important to neurological disease diagnosis, particularly dementia, given the dearth of evidence-based guidelines and reliable technologies for facilitating assessment and diagnosis for the globally aging population,” said Dr. Jay Wohlgemuth, senior vice president and chief medical officer at Quest, in the statement.
- read the statement
Merck, Amgen bump up Series B to $42.4M for Akili
Cambridge Cognition and Ctrl Group partner to develop first wearables for real-time cognitive health
New York startup trots out video game-like screening device for Alzheimer's